NRP1 and neoplasm: Our lab has previously shown that GAM-specific ablation of NRP1, or global pharmacological inhibition of this co-receptor, slows tumor progression in a mouse model of GB, in a similar fashion, by inhibiting neoangiogenesis and reducing immunosuppressive signaling [20].